AMN107

DRUG4 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Chronic Myeloid LeukemiaChronic Myeloid Leukemia (CML)Gastrointestinal Stromal TumorsLeukemia, Myeloid, Chronic

Phase 2

Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy

CompletedNCT00264160

Novartis PharmaceuticalsLeukemia, Myeloid, Chronic

Start: 2006-05-31End: 2009-08-31Updated: 2017-03-06

Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib

CompletedNCT00718562

Novartis PharmaceuticalsGastrointestinal Stromal Tumors

Start: 2008-09-30End: 2013-07-31Updated: 2017-02-23

Phase 4

Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.

WithdrawnNCT01605981

Novartis PharmaceuticalsChronic Myeloid Leukemia (CML)

Start: 2014-02-28End: 2017-01-31Updated: 2017-04-20

Unknown Phase

Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia

Novartis PharmaceuticalsChronic Myeloid Leukemia

Start: 2006-01-31Updated: 2011-08-26